Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
NYSE MKT:PTN
Holding PTN?
Track your performance easily
PTN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.29 - $5.65
Previous Close$1.37
Volume131.81K
Average Volume (3M)123.57K
Market Cap
$26.54M
Enterprise Value$28.28M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 11, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding19,370,000
10 Day Avg. Volume106,023
30 Day Avg. Volume123,567
Standard Deviation0.25
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)17.13
Price to Sales (P/S)4.56
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.18
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$17.00Price Target Upside1150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Palatin Technologies News
PremiumCompany Announcements
Palatin Technologies Secures Growth with Warrant Exercise Deal
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPalatin's combination approach could significantly impact the field, assuming positive clinical data.
Expertise And FoundationPalatin's extensive clinical, regulatory, and commercialization expertise in sexual dysfunction treatment should provide a solid foundation as the company embarks on this new clinical development journey in the field of ED.
Market PotentialED represents a substantial market characterized by significant unmet medical needs among patients who are unresponsive to PDE5 inhibitors.
Bears Say
Clinical TrialsThe PL9643 MELODY-1 Phase 3 trial in dry eye disease failed to reach statistical significance on the co-primary endpoints.
Drug UsageOver two-thirds (68%) of obese patients stop using GLP-1 agonists within the first year due to side effects, particularly at higher doses, and a plateau effect.
EarningsPalatin posted F3Q’24 earnings including EPS of -$0.53 vs. consensus of -$0.45 and our -$0.48 estimate.
---
Ownership Overview
61.36% Insiders
3.90% Mutual Funds
11.92% Other Institutional Investors
22.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PTN FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest stock price was $1.29 and its highest was $5.65 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Currently, no data Available
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were Palatin Technologies Inc’s earnings last quarter?
Currently, no data Available
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 19,369,917 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Among the largest hedge funds holding Palatin Technologies Inc’s share is Fortress Investment Group LLC. It holds Palatin Technologies Inc’s shares valued at 686.
---
Palatin Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (1150.00% Upside)
$17.00 (1150.00% Upside)
Blogger Sentiment
Bullish
PTN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.88%
12-Months-Change
Fundamentals
Return on Equity
-588.69%
Trailing 12-Months
Asset Growth
-55.46%
Trailing 12-Months
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
---
PTN Earnings Call
Q3 2024
0:00 / 0:00
---
PTN Stock 12 Month Forecast
Average Price Target
$17.00
▲(1150.00% Upside)
Technical Analysis
Aclaris Therapeutics
―
Clearside Biomedical
―
Kintara Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering PTN
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-32.12%
reiterated a buy rating 4 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -32.12% per trade.
---